RxDoctor Payments Data

Merrie Cherry, MD

Child & Adolescent Psychiatry · Lexington, SCNPI 1336287762

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (42.6%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Neurocrine Biosciences, Inc. accounts for 63.1% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $26,873, more than ten times the $252 reported in 2019. Among child & adolescent psychiatry clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$39,328in general payments, 2019–2025

Across 965 payments — averaging $40.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$25K
  • Teva Pharmaceuticals USA, Inc.$2K
  • AbbVie$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Johnson & Johnson$2K
  • Otsuka America Pharmaceutical, Inc.$2K
  • plus $5K from 15 others

What the payments were for

  • Consulting fees$6,80017%
  • Speaking & faculty fees$13,00033%
  • Travel & lodging$2,6167%
  • Food & beverage$16,75143%
  • Education$1610%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,328 in reported general payments places this provider in the 95th percentile of 71 child & adolescent psychiatry providers in South Carolina.

See all child & adolescent psychiatry providers in South Carolina

Medicare billing

Part B allowed, 2024
$60,709
Medicare patients
157
Services billed
868

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate73$642,380
Invega TrinzaPaliperidone Palmitate19$196,321
VraylarCariprazine Hcl82$124,532
Abilify MaintenaAripiprazole39$113,266
RexultiBrexpiprazole56$99,222
CaplytaLumateperone Tosylate51$93,858
PerserisRisperidone29$90,191
Invega SustennaPaliperidone Palmitate33$87,217
AristadaAripiprazole Lauroxil19$68,205
TrintellixVortioxetine Hydrobromide90$51,125
BelsomraSuvorexant57$25,724
Lurasidone Hcl92$22,163
Paliperidone ErPaliperidone96$15,388
Aripiprazole183$11,815
Asenapine Maleate55$9,456

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$24,822$642,38073 claims
Johnson & JohnsonInvega Trinza, Invega Sustenna$1,903$283,53852 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$1,658$212,48895 claims
AbbVieVraylar$2,052$124,53282 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$2,029$93,85851 claims
Indivior Inc.Perseris$467$90,19129 claims
Alkermes, Inc.Aristada$1,489$68,20519 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$263$51,12590 claims
MerckBelsomra$61$25,72457 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 71 child & adolescent psychiatry providers in South Carolina.

Other child & adolescent psychiatry in Lexington

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →